Emotional Brain is based in Almere, the Netherlands, and conducts fundamental scientific research into the causes of female sexual dysfunction and clinical research into treatment options. Two new on-demand drugs with blockbuster potential, Lybrido and Lybridos, are in development.
Moreover, Emotional Brain recently developed a novel method, based on genotyping using Single-Nucleotide Polymorphisms (SNPs) resulting in Phenotype Prediction Score (PPS) associated with traits and treatment effects. This innovative genetic method can be applied for the prediction whether someone is a responder or a non-responder to drug use (or traits). Other products are in early development stage. Over the years, Emotional Brain has published numerous well-cited papers in respected, peer-reviewed scientific journals such as Archives of General Psychiatry, the Journal of Sexual Medicine, Psychoneuroendocrinology and the British Journal of Clinical Pharmacology.